An interventional study of Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention, in Schizo-affective Disorder, Non Organic Psychosis and Schizophenia Disorder, sponsored by University of Geneva, Switzerland. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by University of Geneva, Switzerland · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if a group therapy called the Positive Emotions Program for Schizophrenia (PEPS) can reduce apathy in adults aged 18 to 60 who have schizophrenia or a related psychotic disorder. Apathy means having little motivation or drive and getting less pleasure from daily life. The trial will also look at how the brain responds to this therapy.
The main questions it aims to answer are:
Do people who take part in PEPS have less apathy after the therapy than people who continue with their usual care? Does PEPS increase activity in a brain areas important for motivation? Are changes in brain activity linked to changes in apathy?
Researchers will compare PEPS with usual care (regular visits with the treating psychiatrist and nurse, without PEPS) to see if PEPS reduces apathy. They will also compare brain scans of people with schizophrenia to those of healthy volunteers, to see whether brain activity after PEPS becomes more similar to that of people without the illness.
Participants with schizophrenia will:
Background: Negative symptoms of schizophrenia, particularly apathy (avolition, asociality, anhedonia), are a major cause of poor functional outcome, and no pharmacological treatment adequately improves them. The Positive Emotions Program for Schizophrenia (PEPS) is a group psychotherapy that targets deficits in anticipating and maintaining positive emotions. It has reduced apathy and anhedonia compared with treatment as usual in a previous randomized trial (Favrod et al., 2019). The neural mechanisms of this effect are unknown. Ventral striatal hypoactivation during reward anticipation, which is associated with apathy, is a candidate response biomarker.
Objectives: The primary objective is to test the efficacy of PEPS on apathy compared with treatment as usual (TAU). Secondary objectives are to test whether PEPS changes ventral striatal activation during reward anticipation, whether neural changes are associated with clinical improvement, and whether PEPS affects emotion processing, social decision-making and resting-state networks.
Design: This is a single-centre, rater-blinded randomized controlled trial at the Geneva University Hospitals. Eighty-eight outpatients with schizophrenia, schizoaffective disorder or unspecified nonorganic psychosis (aged 18-60, clinically stable, with at least one moderate negative symptom) are randomized 1:1, stratified by sex, to PEPS or TAU. PEPS consists of eight weekly 1-hour group sessions, with about four participants per group. TAU is routine outpatient care, and TAU participants are offered PEPS after completing the study. Thirty healthy controls are also recruited, without randomization or intervention, to provide test-retest benchmarks. All participants undergo clinical assessment and fMRI at baseline and within 2 weeks after the 8-week intervention or waiting period.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
This study's planned enrollment of 88 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Browse Psychotic Disorders studies →University of Geneva, Switzerland is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive the Positive Emotions Program for Schizophrenia (PEPS) in addition to their usual outpatient care. PEPS consists of eight weekly 1-hour group sessions led by a psychologist. Sessions train skills to anticipate, savour, express and share positive emotions, and to challenge defeatist beliefs, with home exercises between sessions.
Behavioral: Positive Emotion Program for Schizophrenia (PEPS), a psychotherapeutic intervention,
Patients continue their usual outpatient care for 8 weeks without PEPS. Usual care includes regular follow-up by their psychiatrist and nurse, antipsychotic medication, and non-specific group activities. None of these specifically targets negative symptoms. Patients are offered PEPS after completing the study.
PEPS is a manualized group intervention delivered over eight weekly sessions. Groups include four to eight participants and each session lasts approximately one hour. The intervention focuses on four main domains: * identifying and savouring positive experiences; * emotional expression; * challenging negative beliefs related to performance; and maximise positive experiences * anticipating and recognizing positive moments in daily life. The intervention uses standardized materials and home exercises to ensure consistency and encourage real-life application.
Apathy score on the Brief Negative Symptom Scale (BNSS)
Apathy is measured with the BNSS apathy composite score. The score is the sum of seven items: three for anhedonia (intensity of pleasure during activities, frequency of pleasurable activities, intensity of expected pleasure from future activities), two for asociality (behaviour and internal experience), and two for avolition (behaviour and internal experience). Each item is rated from 0 to 6 in a clinical interview by a blinded rater. The total score ranges from 0 to 42, and higher scores mean more severe apathy. The post-intervention score is compared between the PEPS and treatment-as-usual groups, adjusted for the baseline score.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period
Ventral striatal activation during reward anticipation
Brain activity (fMRI BOLD signal) in the ventral striatum during reward anticipation in the Monetary Incentive Delay task. Post-intervention activation is compared between the PEPS and treatment-as-usual groups, adjusted for baseline activation.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Association between change in ventral striatal activation and change in apathy
Relationship between post-intervention ventral striatal activation during reward anticipation (Monetary Incentive Delay task) and post-intervention apathy (BNSS apathy composite score). Both are adjusted for their baseline values.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Fronto-limbic connectivity during emotion processing
Task-related functional connectivity (psychophysiological interaction) between the dorsolateral prefrontal cortex, caudate nucleus, anterior cingulate cortex and amygdala during the Variable Affective Attention Task. Post-intervention connectivity is compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Prefrontal activation and fronto-striatal connectivity during social decision-making
Prefrontal activation and prefrontal-striatal functional connectivity (fMRI) during a social-context decision-making task. Post-intervention values are compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Resting-state functional connectivity
Functional connectivity between brain regions measured with resting-state fMRI, including network (graph-theory) measures. Post-intervention connectivity is compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Positive symptoms on the Positive and Negative Syndrome Scale (PANSS)
PANSS positive factor score, the sum of six items (delusions, hallucinatory behaviour, grandiosity, suspiciousness, unusual thought content, lack of judgement and insight). The post-intervention score is compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Self-rated negative symptoms (Self-evaluation of Negative Symptoms, SNS)
Total score on the SNS, a 20-item self-report questionnaire covering anhedonia, avolition, social withdrawal, blunted affect and alogia. The post-intervention score is compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
Cognition (Brief Assessment of Cognition in Schizophrenia, BACS)
BACS composite score across verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, and executive function. The post-intervention score is compared between groups, adjusted for baseline.
Time frame: Baseline, and within 2 weeks after the end of the 8-week intervention or treatment-as-usual period.
No study locations are listed for this record.
Plan to share: Undecided — Sharing of anonymized individual participant data is possible only if the participant has agreed to this option in the informed consent form.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 23 months is below that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Geneva, Switzerland